1. Scrip
  2. >>Business

Takeda Sees Strong Fundamentals Despite Post-Shire Loss Outlook

 
• By Ian Haydock

Post-Shire Takeda expects losses in its first annual forecast for the combined business, plus "significant headwinds" from expected Velcade erosion. But underlying new and legacy Takeda business is seen remaining strong.

Takeda Tokyo HQ entrance
Shire Deal To Move Takeda Into Large Annual Loss • Source: Takeda

In its first full fiscal year outlook since completing the $62bn acquisition of Shire PLC in early January, Takeda Pharmaceutical Co. Ltd. expects the newly merged business to achieve "flat to slightly declining" underlying revenue growth, affected in part by increased US generic competition to one of its top products.

A mid-twenties percentage increase in underlying core earnings margin is foreseen, while underlying core EPS should be in the JPY350-370...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.